Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Robert McQueen to Cost-Benefit Analysis

This is a "connection" page, showing publications Robert McQueen has written about Cost-Benefit Analysis.

 
Connection Strength
  
 
 
3.741
  
  1. Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value Health. 2020 12; 23(12):1523-1533.
    View in: PubMed
    Score: 0.549
  2. McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. Pharmacoeconomics. 2018 08; 36(8):957-971.
    View in: PubMed
    Score: 0.471
  3. Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.
    View in: PubMed
    Score: 0.190
  4. Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
    View in: PubMed
    Score: 0.185
  5. DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
    View in: PubMed
    Score: 0.172
  6. Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
    View in: PubMed
    Score: 0.170
  7. McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? Pharmacoeconomics. 2023 03; 41(3):321-327.
    View in: PubMed
    Score: 0.160
  8. Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Pharmacoeconomics. 2020 11; 38(11):1201-1218.
    View in: PubMed
    Score: 0.138
  9. Synnott PG, McQueen RB, Ollendorf DA, Campbell JD, Pearson SD. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. J Manag Care Spec Pharm. 2020 Jun; 26(6):782-785.
    View in: PubMed
    Score: 0.134
  10. McQueen RB, Geno Rasmussen C, Waugh K, Frohnert BI, Steck AK, Yu L, Baxter J, Rewers M. Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. Diabetes Care. 2020 07; 43(7):1496-1503.
    View in: PubMed
    Score: 0.133
  11. McQueen RB, Whittington MD, Chapman RH, Kumar VM, Campbell JD. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics. 2019 07; 37(7):963-964.
    View in: PubMed
    Score: 0.125
  12. Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm. 2019 Jan; 25(1):80-87.
    View in: PubMed
    Score: 0.121
  13. McQueen RB, Breton MD, Craig J, Holmes H, Whittington MD, Ott MA, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England. J Diabetes Sci Technol. 2018 09; 12(5):992-1001.
    View in: PubMed
    Score: 0.115
  14. McQueen RB, Padula WV, Campbell JD. A Call for Open-Source Cost-Effectiveness Analysis. Ann Intern Med. 2018 04 03; 168(7):528-529.
    View in: PubMed
    Score: 0.115
  15. Padula WV, McQueen RB, Pronovost PJ. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. Med Care. 2017 11; 55(11):909-911.
    View in: PubMed
    Score: 0.112
  16. Padula WV, McQueen RB, Pronovost PJ. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. Med Care. 2017 11; 55(11):915-917.
    View in: PubMed
    Score: 0.112
  17. van Boven JF, McQueen RB, Price DB. COPD case finding: effective, but also cost-effective? Lancet Respir Med. 2016 10; 4(10):e49.
    View in: PubMed
    Score: 0.104
  18. McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72.
    View in: PubMed
    Score: 0.096
  19. McQueen RB, Breton MD, Ott M, Koa H, Beamer B, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. J Diabetes Sci Technol. 2015 Aug 14; 10(2):366-77.
    View in: PubMed
    Score: 0.096
  20. Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. Med Decis Making. 2015 07; 35(5):596-607.
    View in: PubMed
    Score: 0.091
  21. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205.
    View in: PubMed
    Score: 0.086
  22. DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 Apr; 27(4):329-333.
    View in: PubMed
    Score: 0.046
  23. Rind DM, McQueen RB, Herron-Smith S, Herce-Hagiwara B, Gutierrez E, Campbell JD, Fluetsch N, Pearson SD. The effectiveness and value of tezepelumab for severe asthma. J Manag Care Spec Pharm. 2022 May; 28(5):577-580.
    View in: PubMed
    Score: 0.038
  24. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019 02 01; 2(2):e190035.
    View in: PubMed
    Score: 0.030
  25. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018 12 01; 172(12):1161-1168.
    View in: PubMed
    Score: 0.030
  26. Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA Pediatr. 2018 05 01; 172(5):409-410.
    View in: PubMed
    Score: 0.029
  27. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
    View in: PubMed
    Score: 0.026
  28. Dilokthornsakul P, McQueen RB, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD. Value of Information in Asia: Concepts, Current Use, and Future Directions. Value Health Reg Issues. 2016 May; 9:99-104.
    View in: PubMed
    Score: 0.025
  29. Campbell JD, McQueen RB, Briggs A. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl 2:S105-11.
    View in: PubMed
    Score: 0.022
  30. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)